Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
3B Future Health Fund I & II was established in 2016 by Riccardo Braglia, an expert in drug development. The fund is headquartered in Luxembourg and focuses on venture capital investments in early-stage healthcare companies. It aims to support innovative firms that address significant unmet medical needs, particularly in oncology and rare diseases. Since its inception, the fund has successfully invested in over 20 startups and achieved its first exit in 2019 with the acquisition of AMAL Therapeutics.
The fund has a global investment strategy, primarily targeting companies in North America, Europe, and Asia. It has built a reputation for its commitment to addressing high unmet medical needs through strategic investments. The team comprises experienced professionals in drug development and healthcare, which enhances the fund's ability to provide valuable insights and support to its portfolio companies.
3B Future Health Fund I & II primarily invests in early-stage companies located in the US, Europe, and Israel. The fund targets sectors with significant unmet patient needs, focusing on healthcare, biotech, and digital health, with a particular emphasis on oncology and rare diseases. While it typically engages with companies raising Series A rounds, it remains open to investing at earlier stages, including seed funding.
The fund aims to build a diversified portfolio of 10-15 companies, with investments ranging from $1 million to $12 million per company. It also reserves capital for follow-on rounds to support the growth of its portfolio companies. The fund's investment strategy is designed to facilitate the development of innovative solutions that can significantly impact patient care.
3B Future Health Fund I & II has invested in a variety of startups, with notable companies including:
These investments reflect the fund's commitment to supporting innovative healthcare solutions that address critical medical challenges.
Riccardo Braglia, MBA - Chairman and General Partner. Riccardo has extensive experience in drug development and has led numerous successful investments in the healthcare sector.
Francesco Granata, MD - Strategic Advisor and General Partner. Francesco brings a medical background and strategic insight to the fund's investment decisions.
Roberto De Ponti, PharmD - General Partner. Roberto has a strong pharmaceutical background and expertise in drug development.
Francesco Giavatto, MBA - Chief Financial Officer and General Partner. Francesco oversees the fund's financial operations and strategic planning.
Marianne Bjordal, PhD, MBA - General Partner. Marianne has a background in healthcare and investment management, contributing to the fund's strategic direction.
Alessandro Santoboni - Managing Director and General Partner. Alessandro plays a key role in managing the fund's portfolio and investment strategy.
Karin Hehenberger, MD, PhD - Strategic Advisor. Karin provides medical expertise and guidance on investment opportunities.
Sandra van Essche, JD - Corporate Affairs Advisor. Sandra advises on legal and corporate governance matters.
Paolo Paoletti, MD - Strategic Advisor. Paolo offers insights into clinical development and healthcare trends.
Carlos von Bonhorst, MD - Strategic Advisor. Carlos provides medical and strategic insights to the fund.
Stefano Coco, MSc - Associate. Stefano supports the investment team in evaluating opportunities and managing portfolio companies.
To pitch to 3B Future Health Fund, founders should use the preferred channel available on their website at 3bfuturehealth.com. The pitch deck should include a comprehensive overview of the business, including the team, market opportunity, product innovation, and financial projections. Founders can expect a response within a few weeks, and warm introductions are encouraged to enhance the chances of engagement.
In 2019, 3B Future Health Fund achieved its first exit with the acquisition of AMAL Therapeutics, marking a significant milestone for the fund. The fund has continued to actively invest in innovative healthcare startups, with over 20 investments made to date.
Recent highlights include significant funding rounds for portfolio companies such as iOnctura, which received EUR 17.5 million for its pancreatic cancer therapy development, and Sibylla Biotech, which raised €23 million to advance its protein degradation pipeline. These developments indicate ongoing momentum in the healthcare innovation space.
What are the investment criteria for 3B Future Health Fund?
The fund primarily invests in early-stage healthcare companies that address significant unmet medical needs, particularly in oncology and rare diseases. It typically engages with companies raising Series A rounds but is open to earlier-stage investments.
How can startups apply or pitch to 3B Future Health Fund?
Startups can pitch through the fund's website at 3bfuturehealth.com. It is advisable to include a detailed business plan and information on the team, market opportunity, and product innovation in the pitch deck.
What makes 3B Future Health Fund different from other investors?
The fund's focus on early-stage healthcare innovation, particularly in oncology and rare diseases, sets it apart. The experienced team provides strategic support and industry connections to help portfolio companies grow.
What is the geographic scope of 3B Future Health Fund's investments?
The fund primarily invests in companies located in North America, Europe, and Israel, targeting sectors with substantial unmet patient needs.
What is the typical check size for investments?
3B Future Health Fund typically invests between $1 million and $12 million in each company, depending on the stage and needs of the startup.
What is the fund's post-investment involvement like?
The fund provides ongoing support to its portfolio companies, leveraging its team's expertise in drug development and healthcare to facilitate growth and strategic direction.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.